- Home
- AZN
AZN
AstraZeneca PLC
as 05-08-2025 4:00pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 205.5B | IPO Year: | 1993 |
| Target Price: | $92.33 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 4.97 | EPS Growth: | 22.71 |
| 52 Week Low/High: | $61.24 - $87.68 | Next Earning Date: | 04-29-2025 |
| Revenue: | $54,982,000,000 | Revenue Growth: | 15.48% |
| Revenue Growth (this year): | 9.27% | Revenue Growth (next year): | 6.02% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
18 hours ago
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
Simply Wall St.
a day ago
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
MT Newswires
2 days ago
AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study
Thomson Reuters StreetEvents
2 days ago
Q1 2025 Arcus Biosciences Inc Earnings Call
Pharmaceutical Technology
2 days ago
Expediting parallel drug approval pathways is challenging, but rewarding
Business Wire
2 days ago
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
Pharmaceutical Technology
2 days ago
EC approves AstraZeneca’s Calquence combo to treat MCL
GuruFocus.com
2 days ago
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.